Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Annexon, Inc. is a clinical-stage biopharmaceutical company developing novel complement-targeting therapies for inflammatory diseases. Its proprietary platform focuses on inhibiting C1q to block the classical complement pathway implicated in autoimmune, neurodegenerative, and ophthalmologic disorders. Key programs include treatments for Guillain-Barré Syndrome, geographic atrophy in dry AMD, and autoimmune diseases. Annexon holds global rights to its pipeline, leveraging targeted inhibition to preserve immune function while addressing unmet medical needs.
This description was generated via AI from an annual report. Updated about 1 year ago.